Allarity Therapeutics, Inc. ALLR
At closeNov 6, 2026, 4:00 PM EST
After hours · Nov 6, 4:00 PM ET
- YTD
- -10.66%
- 1 year
- -13.07%
- Market cap
- 15.35M
- EPS (ttm)
- -0.79
- Shares out
- 4.43M
- Forward P/E
- -0.02
- YTD return
- -10.66%
- 1-year return
- -13.07%
- Volume
- 64.31K
- Avg volume
- 118.02K
- Open
- 0.96
- Previous close
- 0.9702
- Day's range
- 0.96 – 0.99
- 52-week range
- 0.81 – 1.77
- Beta
- 0.29
- Earnings date
- Aug 5, 2024
1Y -0.1850 (-16.09%)
Key statistics
- Enterprise value
- -15.92M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -12.94M
- Total cash
- 19.23M
- Total debt
- 1.32M
- Return on equity
- -121.82%
- Short % of float
- 12.70%
- 50-day average
- 1.30
- 200-day average
- 28.72
Next earnings
Aug 5, 2024
Expected Aug 5, 2024. Consensus EPS estimate -8.10.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -7.71 | — | — |
| Aug 5, 2024 | Jun 1, 2024 | 0.00 | -3.30 | — | — |
| Aug 5, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -664.86 | — | — |
| Mar 8, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
About Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- allarity.com
News
Allarity Therapeutics Settles $4.9M Novartis Liability For $1M Payment 
Allarity Therapeutics Terminates $6M Equity Purchase Agreement With Tumim Stone Capital To Pursue Alternative Financing; Says No Early Termination Penalty Is Payable 
Allarity Therapeutics Receives First Contract For Its Development, Validation And Related Laboratory Services From Undisclosed European Biotech Firm - Allarity Therapeutics Highlights DRP Technology, Patent And Lab Advances To Support Stenoparib Development And Partnerships
Allarity Therapeutics Expands Capabilities Of Its In-House Medical Laboratory To Include Proteomics And Cell Line Research 
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket 
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday 
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11 - Allarity Therapeutics Q2 EPS $(0.21) Beats $(0.25) Estimate
- 12 Health Care Stocks Moving In Monday's After-Market Session
Your note
Sign in to keep a note on ALLR — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.42% | 18,452 | 18.73K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.08% | 3,403 | 3.45K | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 11 | 11 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.16% | 7,192 | 7.30K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.06% | 2,601 | 2.64K | Oct 30, 2024 |